Use to measure rivaroxaban concentration.
New York DOH Approval Status
Lt. blue (sodium citrate). Refer to Specimen Handling at aruplab.com for hemostasis/thrombosis specimen handling guidelines.
Transport 2 mL platelet-poor plasma. (Min: 1 mL)
CRITICAL FROZEN. Separate specimens must be submitted when additional tests are ordered
Serum. EDTA, oxalate, heparin, or plasma separator tubes, hemolyzed specimens.
This test cannot be used to quantitate anticoagulants other than Rivaroxaban. This includes but is not limited to Unfractionated Heparin, Low Molecular Weight Heparin, Apixaban (Eliquis), Edoxaban (Savaysa), and Fondaparinux (Arixtra).
After separation from cells: Ambient: 4 hours; Refrigerated: Unacceptable; Frozen: 1 month
When 20 mg rivaroxaban was administered daily for treatment of DVT and PE, rivaroxaban steady state levels were as follows:
Peak: 189-419 ng/mL
Trough: 6-87 ng/mL
The lower limit of detection for this assay is 25 ng/mL.
For additional information, please refer to For additional information, please refer to www.arupconsult.com
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
- Direct oral anti coagulant
- Direct oral anti-coagulant
- Direct oral anticoagulant